Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRABiotechnology
-$0.10 today
- Market cap
- $69.21M
- Beta
- 2.76
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$1.24
Volume 1.50M
Average 2.02M
NMRA Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Neumora Therapeutics, Inc. Common StockNASDAQ: NMRA
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $53.46M (cash outflow) fell 21.4% year over year, behind the -13.8% change in trailing-twelve-month net income. Sequentially, it fell 10.1% from the prior quarter. Over 3 fiscal years it compounded at +21.9% a year.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 9 analysts of -$179.26M (-24.3%) for the fiscal year ending Dec 2026, a slowdown from the -2.8% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$53.46M-10.1% QoQ
- Last fiscal yearDec 2025
- -$236.93M-2.8% YoY
- LTMMar 2026
- -$222.39M-13.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -21.4% | -18.6% | +2.7 pp |
| 1 year | -2.8% | -24.3% | -21.5 pp |
| 3-year CAGR | +21.9% | -23.6% | -45.5 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (236.93M) USD
- Year-over-year change
- +2.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (236.93M) | +2.8% |
| FY2024 | 2024-12-31 | (243.79M) | -3.3% |
| FY2023 | 2023-12-31 | (235.93M) | -80.2% |
| FY2022 | 2022-12-31 | (130.9M) | +44.8% |
| FY2021 | 2021-12-31 | (237.31M) | — |
Net Income vs competitors
How NMRA compares with its peers on the latest reported figures
- NMRA's LTM Mar 2026 net income of $222.39M is the 3rd largest of the 10 companies compared; the peer median is $151.18M.
- Its year-over-year change of -13.8% is the 9th highest of 10, against a peer median of +21.3%.
- Over three fiscal years its annual growth of +21.9% compares with a peer median of +9.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $438.96M | +92.9% | +29.5% | 5933.5% |
| LTM Mar 2026 | $288.97M | +21.3% | +24.5% | 312.1% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $222.39M | -13.8% | +21.9% | — |
| LTM Mar 2026 | $218.8M | +7.2% | +24.8% | 344.6% | |
| LTM Mar 2026 | $160.9M | -8.8% | +9.2% | 182.3% | |
| LTM Mar 2026 | $151.18M | +37.1% | +27.8% | 260.9% | |
| LTM Mar 2026 | $136.99M | -8.6% | -3.2% | 173.0% | |
| LTM Mar 2026 | $81.36M | +148.9% | -73.6% | 822.4% | |
| LTM Mar 2026 | $76.12M | +14824.7% | -12.0% | — | |
| LTM Mar 2026 | $26.09M | -85.3% | -21.0% | 37.5% | |
| Peer median (excluding NMRA) | $151.18M | +21.3% | +9.2% | 286.5% | |
Competitors are the stored peer set for NMRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (237.31M) | (130.9M) | (235.93M) | (243.79M) | (236.93M) |
| Depreciation & Amortization | 538K | 594K | 668K | 631K | 208K |
| Deferred Income Tax | (53K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.27M | 8.3M | 17.24M | 39.99M | 29.88M |
| Change in Working Capital | (961K) | (6.95M) | (8.9M) | 22.64M | (437K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (759K) | (1.25M) | (581K) | 2.87M | 71K |
| Other Working Capital | (202K) | (5.7M) | (8.32M) | 19.76M | (508K) |
| Other Non-Cash Items | 158.09M | 14.06M | 63.64M | (1.78M) | 841K |
| Operating Cash Flow | (75.42M) | (114.9M) | (163.28M) | (182.94M) | (206.44M) |
| Capital Expenditures | (817K) | (511K) | (117K) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | (775K) | 0 |
| Purchases of Investments | 0 | (226.37M) | (109.07M) | (312.22M) | (85.8M) |
| Sales of Investments | 0 | 71.87M | 178.17M | 242.44M | 251.17M |
| Other Investing Activities | 0 | (13M) | (4.59M) | 0 | 3.15M |
| Investing Cash Flow | (817K) | (168.01M) | 64.39M | (70.56M) | 168.52M |
| Debt Repayment | 0 | 0 | 0 | 0 | 57.16M |
| Common Stock Issued | 960K | 0 | 233.38M | 13.69M | 19.93M |
| Common Stock Repurchased | 0 | 0 | (491K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.37M | 3.53M | (948K) | 7.91M | 0 |
| Financing Cash Flow | 293.51M | 115.74M | 231.94M | 21.6M | 77.09M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 217.27M | (167.17M) | 133.05M | (231.89M) | 39.17M |
| Free Cash Flow | (76.24M) | (115.41M) | (163.4M) | (182.94M) | (206.44M) |
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
Intrinsic Alpha fair value
Locked
Current Price
$0.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.